Eli Lilly’s (LLY) olomorasib was granted FDA orphan designation as a treatment of KRAS G12C-mutant NSCLC, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s LY3971297 Study: A Potential Game-Changer in Drug Safety Evaluation
- Eli Lilly’s Orforglipron Study: A Step Forward in Drug Delivery
- Eli Lilly’s New Study on LY4100511: What Investors Need to Know
- Eli Lilly’s Orforglipron Study: A Step Forward in Drug Development
- California seeks to cut Medicaid coverage for weight loss drugs, Bloomberg says